WHO urges investments for the scale up of tuberculosis screening and preventive treatment

March 20, 2024
2024 World Tuberculosis Day is being commemorated under the theme 'Yes! We can end TB!'

Ahead of World Tuberculosis (TB) Day, which is marked on March 24, the World Health Organization (WHO) has released an investment case for TB screening and preventive treatment.

A modelling study developed with Governments of four countries - Brazil, Georgia, Kenya and South Africa - highlights the impact to be achieved from expanding TB screening and preventive treatment.

The analysis shows that modest investments could lead to significant health and economic benefits in all four countries, with a return on investment up to US$ 39 gained for every dollar invested. The investment case has been released to support countries in advocating for and allocating increased resources to scale-up TB screening and preventive treatment towards reaching new targets committed by Heads of State at the 2023 UN High-Level Meeting on TB.

According to the investment report, implementing TB screening plus preventive treatment can substantially reduce TB incidence and mortality. It argues that these crucial public health investments are essential for addressing the needs of vulnerable populations and achieving the End TB targets.

In 2022, WHO reported a significant worldwide recovery in the scale-up of access to TB diagnosis and treatment services, with the highest figure recorded since WHO began global TB monitoring in 1995.

However, the scale-up of access to TB preventive treatment has been slow. Preventing TB infection and stopping progression from infection to disease are critical for reducing TB incidence to the levels envisaged by the WHO’s End TB Strategy. To do this, it is vital to offer TB preventive treatment to those with HIV, household contacts of TB patients, and other high-risk groups.

The global number of people living with HIV and household contacts of people with TB who were provided with TB preventive treatment increased to 3.8 million in 2022 or about 60% of those targeted that year in line with the commitments made at the UN High-Level Meeting of 2018.

Multidrug-resistant TB (MDR-TB) remains a public health crisis. While an estimated 410 000 people developed multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) in 2022, only about 2 in 5 people accessed treatment. Progress in the development of new TB diagnostics, drugs and vaccines remains constrained by the overall level of investment in these areas.

2024 World Tuberculosis Day is being commemorated under the theme 'Yes! We can end TB!'

The global targets approved at the 2023 UN High-Level Meeting on TB include: reaching 90% of people in need with TB prevention and care services; using a WHO-recommended rapid test as the first method of diagnosing TB; providing a health and social benefit package to all people with TB; ensuring the availability of at least one new TB vaccine that is safe and effective; and closing funding gaps for TB implementation and research by 2027.

WHO release